Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
Trial details
- Registry ID
- NCT06431776
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Recombinant human GM-CSF; Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF); Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF).
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).NCT06431776 | SVRA | Phase 3 | Recruiting | 2027-06Estimated |
| Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar ProteinosisNCT03482752 | SVRA | Phase 3 | Terminated | 2021-01-14Actual |
| Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)NCT04544293 | SVRA | Phase 3 | Active not recruiting | 2023-11-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |